{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:51:17Z","timestamp":1791294677079,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.critrevonc.2014.10.010","type":"journal-article","created":{"date-parts":[[2014,10,31]],"date-time":"2014-10-31T01:47:49Z","timestamp":1414720069000},"page":"159-169","source":"Crossref","is-referenced-by-count":11,"title":["In vivo model for mastocytosis: A comparative review"],"prefix":"10.1016","volume":"93","author":[{"given":"Girolamo","family":"Ranieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Marech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Piccinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roncetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Mutinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmo Damiano","family":"Gadaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Introna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele Luigi","family":"Sciorsci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3 Suppl.","key":"10.1016\/j.critrevonc.2014.10.010_bib0005","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1111\/1523-1747.ep12468899","article-title":"Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital","volume":"96","author":"Horan","year":"1991","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0010","first-page":"2S","article-title":"Classification and diagnosis of mastocytosis: current status","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0015","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.4049\/jimmunol.146.5.1410","article-title":"Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells","volume":"146","author":"Kirshenbaum","year":"1991","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.critrevonc.2014.10.010_bib0020","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1590\/S0102-09352010000600008","article-title":"Mast cells and angiogenesis in canine mammary tumor","volume":"62","author":"Lavalle","year":"2010","journal-title":"Arquivo Bras Med Vet Zoot"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0025","series-title":"Cellular and molecular immunology","author":"Abbas","year":"2000"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0030","series-title":"Tumor in domestic animals","first-page":"45","article-title":"Tumors of the skin and soft tissues","author":"Goldschmidt","year":"2002"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0035","first-page":"1317","article-title":"Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma","volume":"21","author":"Ranieri","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0040","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of mieloid cells in the promotion of tumor angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0045","first-page":"1189","article-title":"The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy","volume":"10","author":"Ranieri","year":"2003","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.critrevonc.2014.10.010_bib0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1582-4934.2008.00355.x","article-title":"VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model","volume":"13","author":"Patruno","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2014.10.010_bib0055","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1177\/104063870902100608","article-title":"Nuclear morphometry in cytopathology: a prognostic indicator for canine cutaneous mast cell tumors","volume":"21","author":"Strefezzi Rde","year":"2009","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0060","series-title":"Robbins e Cotran- Patologia- Bases pat\u00f2logicas das doen\u00e7as","author":"Kumar","year":"2005"},{"issue":"3","key":"10.1016\/j.critrevonc.2014.10.010_bib0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1590\/S0102-09352002000300006","article-title":"Ultra estrutura dos diferente stipos de mastocitoma canino","volume":"54","author":"Sueiro","year":"2002","journal-title":"Arquivo Bras Med Vet Zoot"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0070","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1091\/mbc.9.4.875","article-title":"Synthesis, storage, and release of vascular endothelial growth factor\/vascular permeability factor (VEGF\/VPF) by human mast cells: implications for the biological significance of VEGF206","volume":"9","author":"Grutzkau","year":"1998","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0075","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4049\/jimmunol.174.12.7665","article-title":"Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor","volume":"174","author":"Cao","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0080","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0002-9440(10)63442-6","article-title":"Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis","volume":"163","author":"Hartmann","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000048180","article-title":"Histopathological and immunohistochemical aspects of mastocytosis","volume":"127","author":"Horny","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0090","first-page":"197","article-title":"Systemic mastocytosis: current concepts and treatment advances","volume":"3","author":"Tefferi","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0095","doi-asserted-by":"crossref","first-page":"115S","DOI":"10.1111\/1523-1747.ep12468942","article-title":"Mastocytosis","volume":"96","author":"Kettelhut","year":"1991","journal-title":"J Investig Dermatol"},{"issue":"3","key":"10.1016\/j.critrevonc.2014.10.010_bib0100","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1111\/1523-1747.ep12468942","article-title":"Pediatric mastocytosis","volume":"96","author":"Kettelhut","year":"1991","journal-title":"J Investig Dermatol"},{"issue":"4","key":"10.1016\/j.critrevonc.2014.10.010_bib0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/ped.2013.0275","article-title":"Pediatric mastocytosis: a review of the literature","volume":"26","author":"Frieri","year":"2013","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2500\/108854189778968551","article-title":"Mastocytosis in infants and children: recognition of patterns of skin disease","volume":"10","author":"Kirshenbaum","year":"1989","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0115","series-title":"World Health Organization classification of tumors: pathology and genetics of tumours of haematopoietic and lymphoid tissues","article-title":"Mastocytosis","author":"Valent","year":"2001"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0120","first-page":"33","article-title":"Mastocytosis: classification, diagnosis and clinical presentation","volume":"25","author":"Castells","year":"2004","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"10.1016\/j.critrevonc.2014.10.010_bib0125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1365-2133.2001.04123.x","article-title":"Mastocytosis: recent advances in defining the disease","volume":"144","author":"Hartmann","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0190-9622(82)70152-5","article-title":"Mastocytosis and the mast cell","volume":"7","author":"DiBacco","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.10.010_bib0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.critrevonc.2014.10.010_bib0140","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/bjp.2008.204","article-title":"Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders","volume":"154","author":"Jensen","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0145","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.iac.2006.05.003","article-title":"KIT mutations in mastocytosis and their potential as therapeutic targets","volume":"26","author":"Gotlib","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60508-8","article-title":"The kit-ligand, stem-cell factor","volume":"55","author":"Galli","year":"1994","journal-title":"Adv Immunol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0160","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0165","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2014.10.010_bib0170","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2353\/jmoldx.2006.060022","article-title":"Molecular diagnosis of mast cell disorder","volume":"8","author":"Akin","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0175","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/j.1460-2075.1995.tb07023.x","article-title":"Differential roles of PI3-Kinase and KIT tyrosine-821 in KIT receptor-mediated proliferation, survival and cell adhesion in mast cells","volume":"14","author":"Serve","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0180","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1074\/jbc.272.9.5915","article-title":"Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr (568\/570) of the activated c-KIT in megakaryocytes","volume":"272","author":"Price","year":"1997","journal-title":"J Chem Biol"},{"issue":"4","key":"10.1016\/j.critrevonc.2014.10.010_bib0185","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.critrevonc.2014.10.010_bib0190","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0195","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0200","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.10.010_bib0205","first-page":"153","article-title":"AgNOR protein expression and tumor growth rate of human carcinoma xenografts growing subcutaneously in nude mice","volume":"41","author":"Trere","year":"1997","journal-title":"Eur J Histochem"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0210","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000048179","article-title":"Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts","volume":"127","author":"Feger","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0215","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2500\/aap.2010.31.3368","article-title":"A solitary mastocytoma presenting with urticaria and angioedema in a 14-year-old boy","volume":"31","author":"Krishnan","year":"2010","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0220","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ajcp\/109.3.279","article-title":"Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults","volume":"109","author":"Topar","year":"1998","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.critrevonc.2014.10.010_bib0225","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Investig"},{"issue":"10","key":"10.1016\/j.critrevonc.2014.10.010_bib0230","first-page":"1106","article-title":"Systemic mast cell disease associated with B-chronic lymphocytic leukemia","volume":"86","author":"Sanz","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0235","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.hoc.2012.08.008","article-title":"New insights into the pathogenesis, diagnosis, and management of mastocytosis","volume":"26","author":"Fuller","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0240","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1748-5827.2007.00366.x","article-title":"Advances in the diagnosis and management of cutaneous mast cell tumours in dogs","volume":"48","author":"Dobson","year":"2007","journal-title":"J Small Anim Pract"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0245","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/030098589202900415","article-title":"Cutaneous mastocytosis in a dog","volume":"29","author":"Davis","year":"1992","journal-title":"Vet Pathol"},{"issue":"8","key":"10.1016\/j.critrevonc.2014.10.010_bib0250","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1001\/archinte.1990.00040031742025","article-title":"Familial urticaria pigmentosa","volume":"150","author":"Clark","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0255","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2460\/javma.239.7.960","article-title":"Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms","volume":"239","author":"Villamil","year":"2011","journal-title":"J Am Vet Med Assoc"},{"issue":"6","key":"10.1016\/j.critrevonc.2014.10.010_bib0260","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-3164.2008.00694.x","article-title":"Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment","volume":"19","author":"Welle","year":"2008","journal-title":"Vet Dermatol"},{"issue":"5","key":"10.1016\/j.critrevonc.2014.10.010_bib0265","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/030098588402100503","article-title":"Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs","volume":"21","author":"Patnaik","year":"1984","journal-title":"Vet Pathol"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.10.010_bib0270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1593\/neo.05622","article-title":"The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors","volume":"8","author":"Webster","year":"2006","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.critrevonc.2014.10.010_bib0275","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2460\/ajvr.2002.63.1718","article-title":"Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs","volume":"63","author":"Downing","year":"2002","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0280","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jcpa.2011.12.003","article-title":"Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours","volume":"147","author":"Rodriguez","year":"2012","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0285","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1354\/vp.39-5-529","article-title":"Mutations in the juxtamembrane domain of c-Kit are associated with higher grade MCTs in dogs","volume":"39","author":"Zemke","year":"2002","journal-title":"Vet Pathol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/104063870501700416","article-title":"A study of mutations in the c-kit gene of 32 dogs with mastocytoma","volume":"17","author":"Riva","year":"2005","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0295","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/104063870601800404","article-title":"Expression of c-kit proto-oncogene in canine mastocytoma: a kinetic study using real-time polymerase chain reaction","volume":"18","author":"Turin","year":"2006","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0300","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0301-472X(98)00075-7","article-title":"Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit","volume":"27","author":"London","year":"1999","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0305","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1354\/vp.44-3-298","article-title":"Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication","volume":"44","author":"Webster","year":"2007","journal-title":"Vet Pathol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0310","first-page":"33473","article-title":"Mast cell tumors in the dog","author":"London","year":"2003","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0315","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.2460\/javma.2005.226.1368","article-title":"Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990\u20132001)","volume":"226","author":"Sfiligoi","year":"2005","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0320","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jcpa.2007.02.003","article-title":"Canine subcutaneous mast cell tumour: diagnosis and prognosis","volume":"136","author":"Newman","year":"2007","journal-title":"J Comp Pathol"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.10.010_bib0325","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1939-1676.1987.tb01990.x","article-title":"Systemic mastocytosis in 16 dogs","volume":"1","author":"O\u2019Keefe","year":"1987","journal-title":"J Vet Intern Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.10.010_bib0330","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1939-1676.2003.tb02433.x","article-title":"Relationship of disease progression and plasma histamine concentrations in 11 dogs with mast cell tumors","volume":"17","author":"Ishiguro","year":"2003","journal-title":"J Vet Intern Med"},{"issue":"1\u20132","key":"10.1016\/j.critrevonc.2014.10.010_bib0335","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jim.2013.01.008","article-title":"A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses","volume":"390","author":"Smr\u017e","year":"2013","journal-title":"J Immunol Methods"},{"issue":"5","key":"10.1016\/j.critrevonc.2014.10.010_bib0340","doi-asserted-by":"crossref","first-page":"e96209","DOI":"10.1371\/journal.pone.0096209","article-title":"Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis","volume":"9","author":"De Vita","year":"2014","journal-title":"PLoS ONE"},{"issue":"23","key":"10.1016\/j.critrevonc.2014.10.010_bib0345","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1182\/blood-2012-02-407163","article-title":"Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40","volume":"120","author":"Yang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0350","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.12999","article-title":"A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis","author":"Balci","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0355","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2460\/javma.232.1.53","article-title":"Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs","volume":"232","author":"Stanclift","year":"2008","journal-title":"J Am Vet Med Assoc"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.10.010_bib0360","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2460\/javma.228.1.91","article-title":"Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumours treated with surgery with and without adjuvant treatment: 54 cases (1998\u20132004)","volume":"228","author":"Mullins","year":"2006","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0365","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1476-5810.2004.00048.x","article-title":"Treatment of canine mast cell tumours with prednisolone and radiotherapy","volume":"2","author":"Dobson","year":"2004","journal-title":"Vet Comp Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.10.010_bib0370","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tvjl.2012.01.033","article-title":"Overexpression of P-glycoprotein, STAT3, phosphor-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment","volume":"193","author":"Teng","year":"2012","journal-title":"Vet J"},{"issue":"4\u20135","key":"10.1016\/j.critrevonc.2014.10.010_bib0375","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0960-0760(02)00223-6","article-title":"Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones","volume":"82","author":"Krasil\u2019nikov","year":"2002","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0380","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0065-230X(08)00406-5","article-title":"Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoidinduced apoptosis","volume":"101","author":"Sionov","year":"2008","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0385","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1074\/jbc.M110.182642","article-title":"Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells","volume":"286","author":"Chaix","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0390","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","article-title":"STATs in oncogenesis","volume":"19","author":"Bowman","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0395","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1517\/14728222.8.5.409","article-title":"STAT proteins as novel targets for cancer drug discovery","volume":"8","author":"Turkson","year":"2004","journal-title":"Exp Opin Ther Targets"},{"issue":"4","key":"10.1016\/j.critrevonc.2014.10.010_bib0400","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s004030050398","article-title":"Glucocorticoids inhibit proliferation and adhesion of the IL-3-dependent mast cell line, MC\/9, to NIH\/3T3 fibroblasts, with an accompanying decrease in IL-3 receptor expression","volume":"291","author":"Sakai","year":"1999","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0405","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1354\/vp.41-4-371","article-title":"The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors","volume":"41","author":"Kiupel","year":"2004","journal-title":"Vet Pathol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0410","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF01525983","article-title":"The immunological effects of interleukin-2 in vivo","volume":"39","author":"Janssen","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.cad.0000182748.47353.51","article-title":"Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma","volume":"17","author":"Grande","year":"2006","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1016\/j.critrevonc.2014.10.010_bib0420","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1751-553X.2012.01427.x","article-title":"Current state of biology and diagnosis of clonal mast cell diseases in adults","volume":"34","author":"Alvarez-Twose","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0425","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0162-3109(97)00041-6","article-title":"Vascular leak syndrome: a side-effect of immunotherapy","volume":"37","author":"Baluna","year":"1997","journal-title":"Immunopharmacology"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.10.010_bib0430","first-page":"161","article-title":"Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs","volume":"33","author":"Ziekman","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0435","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01669425","article-title":"Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study","volume":"30","author":"Rutten","year":"1989","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0440","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF01788954","article-title":"Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regression after 20 months of follow-up","volume":"41","author":"Den Otter","year":"1995","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0445","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/01652176.1998.9694832","article-title":"Multi-agent chemotherapy for mast cell tumours in the dog","volume":"20","author":"Gerritsen","year":"1998","journal-title":"Vet Q"},{"issue":"13","key":"10.1016\/j.critrevonc.2014.10.010_bib0450","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2014.10.010_bib0455","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0460","article-title":"Masitinib (AB1010), from canine tumor model to human clinical development: where we are?","author":"Marech","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.critrevonc.2014.10.010_bib0465","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.10.010_bib0470","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2013.05.009","article-title":"Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review","volume":"88","author":"Ranieri","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"21","key":"10.1016\/j.critrevonc.2014.10.010_bib0475","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/blood-2009-07-231985","article-title":"AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit","volume":"115","author":"Lin","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2014.10.010_bib0480","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0485","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0490","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/1541-7786.MCR-08-0067","article-title":"Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors","volume":"6","author":"Letard","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0495","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.critrevonc.2014.10.010_bib0500","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Mast cell activation syndromes: definition and classification","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy"},{"issue":"1\u20132","key":"10.1016\/j.critrevonc.2014.10.010_bib0505","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cellimm.2012.03.004","article-title":"Polyunsaturated fatty acid supplements modulate mast cell membrane microdomain composition","volume":"275","author":"Basiouni","year":"2012","journal-title":"Cell Immunol"},{"issue":"7","key":"10.1016\/j.critrevonc.2014.10.010_bib0510","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1398-9995.2012.02833.x","article-title":"NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation","volume":"67","author":"Hadzijusufovic","year":"2012","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.critrevonc.2014.10.010_bib0515","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"(PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Br Soc Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.10.010_bib0520","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1748-5827.2012.01304.x","article-title":"Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas","volume":"54","author":"Rivera","year":"2013","journal-title":"J Small Anim Pract"},{"key":"10.1016\/j.critrevonc.2014.10.010_bib0525","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/1535-7163.1301.3.10","article-title":"Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway","volume":"3","author":"Pasquier","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.critrevonc.2014.10.010_bib0530","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/14740338.6.5.609","article-title":"Paclitaxel: a review of adverse toxicities and novel delivery strategies","volume":"6","author":"Marupudi","year":"2007","journal-title":"Exp Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.10.010_bib0535","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00280-004-0855-5","article-title":"Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo","volume":"55","author":"Hassan","year":"2005","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281400170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281400170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T18:38:44Z","timestamp":1689619124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281400170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S104084281400170X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2014.10.010","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}